1. Leukemia. 2016 Nov;30(11):2160-2168. doi: 10.1038/leu.2016.126. Epub 2016 May
3.

RUNX1 mutations in acute myeloid leukemia are associated with distinct 
clinico-pathologic and genetic features.

Gaidzik VI(1), Teleanu V(1), Papaemmanuil E(2), Weber D(1), Paschka P(1), Hahn 
J(1), Wallrabenstein T(1), Kolbinger B(1), Köhne CH(3), Horst HA(4), Brossart 
P(5), Held G(6), Kündgen A(7), Ringhoffer M(8), Götze K(9), Rummel M(10), 
Gerstung M(2), Campbell P(2), Kraus JM(11), Kestler HA(11), Thol F(12), Heuser 
M(12), Schlegelberger B(12), Ganser A(12), Bullinger L(1), Schlenk RF(1), Döhner 
K(1), Döhner H(1).

Author information:
(1)Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany.
(2)Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, UK.
(3)Klinik für Hämatologie und Onkologie, Klinikum Oldenburg, Oldenburg, Germany.
(4)Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein Campus 
Kiel, Kiel, Germany.
(5)Medizinische Klinik und Poliklinik III, Universitätsklinikum Bonn, Bonn, 
Germany.
(6)Klinik für Innere Medizin I, Universitätskliniken des Saarlandes, Homburg, 
Germany.
(7)Klinik für Hämatologie, Onkologie und Klinische Onkologie, 
Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
(8)Medizinische Klinik III, Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, 
Germany.
(9)III. Medizinische Klinik, Klinikum Rechts der Isar, Technische Universität 
München, München, Germany.
(10)Medizinische Klinik IV, Universitätsklinikum Gießen, Gießen, Germany.
(11)Medical Systems Biology, Universität Ulm, Ulm, Germany.
(12)Klinik für Hämatologie, Hämostaseologie, Onkologie und 
Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany.

Erratum in
    Leukemia. 2016 Nov;30(11):2282. doi: 10.1038/leu.2016.207.

We evaluated the frequency, genetic architecture, clinico-pathologic features 
and prognostic impact of RUNX1 mutations in 2439 adult patients with 
newly-diagnosed acute myeloid leukemia (AML). RUNX1 mutations were found in 245 
of 2439 (10%) patients; were almost mutually exclusive of AML with recurrent 
genetic abnormalities; and they co-occurred with a complex pattern of gene 
mutations, frequently involving mutations in epigenetic modifiers (ASXL1, IDH2, 
KMT2A, EZH2), components of the spliceosome complex (SRSF2, SF3B1) and STAG2, 
PHF6, BCOR. RUNX1 mutations were associated with older age (16-59 years: 8.5%; 
⩾60 years: 15.1%), male gender, more immature morphology and secondary AML 
evolving from myelodysplastic syndrome. In univariable analyses, RUNX1 mutations 
were associated with inferior event-free (EFS, P<0.0001), relapse-free (RFS, 
P=0.0007) and overall survival (OS, P<0.0001) in all patients, remaining 
significant when age was considered. In multivariable analysis, RUNX1 mutations 
predicted for inferior EFS (P=0.01). The effect of co-mutation varied by partner 
gene, where patients with the secondary genotypes RUNX1mut/ASXL1mut (OS, 
P=0.004), RUNX1mut/SRSF2mut (OS, P=0.007) and RUNX1mut/PHF6mut (OS, P=0.03) did 
significantly worse, whereas patients with the genotype RUNX1mut/IDH2mut (OS, 
P=0.04) had a better outcome. In conclusion, RUNX1-mutated AML is associated 
with a complex mutation cluster and is correlated with distinct 
clinico-pathologic features and inferior prognosis.

DOI: 10.1038/leu.2016.126
PMID: 27137476 [Indexed for MEDLINE]